Johnson & Johnson unit ordered to pay $1.64 billion in HIV drug marketing case
A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it ...
The Manila Times4h
Arialief Reviews & Complaints (ALERT): Is This Nerve Pain Breakthrough Too Good To Be Real?
There are also users who don't feel immediate results-and that's expected. Some people have deeply rooted nerve issues that require longer rebuilding cycles. Arialief's team emphasizes that this ...
C&EN4h
12 drug candidates debut in San Diego
BMS-986458 features three stereocenters, one of which epimerizes easily, Mortensen said. The drug candidate, which would be ...
Lexicon Pharmaceuticals, Novo Nordisk strike obesity-drug license deal worth up to $1B
Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX) said March 28 it will exclusively license its drug candidate LX9581 to Danish ...
Healio5h
FDA authorizes marketing of first chlamydia, gonorrhea, trichomoniasis home test
The FDA has granted Visby Medical authorization to market their at-home, over-the-counter diagnostic test that detects ...
BioPharma Dive7h
Lilly hits same Alzheimer’s roadblock in Europe as Eisai, Biogen
Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...
WISH-TV7h
European regulators reject Lilly’s US-approved Alzheimer’s treatment
European regulatory committee rejects Lilly's Alzheimer's disease treatment due to potential risks of brain bleeding and ...
Medscape8h
Alzheimer Drug Donanemab Gets No-Go From European Regulator
The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the treatment of Alzheimer's disease.
European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder
PTC Therapeutics' Translarna loses EU conditional approval, but countries may allow continued use. PTC submitted four FDA ...